1st Global Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$3.95M Sell
124,051
-1,269
-1% -$40K 0.46% 24
2017
Q1
$4.07M Buy
125,320
+1,532
+1% +$48.3K 0.48% 22
2016
Q4
$3.81M Buy
123,788
+7,297
+6% +$223K 0.48% 22
2016
Q3
$3.74M Buy
116,491
+10,377
+10% +$347K 0.49% 18
2016
Q2
$3.54M Sell
106,114
-8,417
-7% -$269K 0.49% 18
2016
Q1
$3.22M Buy
114,531
+7,877
+7% +$225K 0.46% 19
2015
Q4
$3.27M Sell
106,654
-1,178
-1% -$37.1K 0.49% 20
2015
Q3
$3.21M Buy
107,832
+7,058
+7% +$226K 0.51% 20
2015
Q2
$3.21K Sell
100,774
-1,462
-1% -$47.6K 0.47% 22
2015
Q1
$3.38M Sell
102,236
-143
-0.1% -$4.55K 0.5% 18
2014
Q4
$3.03M Buy
102,379
+5,104
+5% +$146K 0.43% 25
2014
Q3
$2.73M Buy
97,275
+1,525
+2% +$42.8K 0.43% 28
2014
Q2
$2.7M Buy
95,750
+4,572
+5% +$130K 0.4% 29
2014
Q1
$2.78M Buy
91,178
+318
+0.3% +$9.48K 0.52% 22
2013
Q4
$2.64M Sell
90,860
-5,086
-5% -$148K 0.49% 25
2013
Q3
$2.62M Buy
95,946
+2,830
+3% +$77K 0.53% 24
2013
Q2
$2.48M Buy
+93,116
New +$2.57M 0.54% 24

Other funds holding PFE

1st Global Advisors's PFE Position: Q2 2017 in Review

1st Global Advisors reduced its Pfizer (PFE) stake by 1% in Q2 2017, selling an estimated $40K and leaving 124,051 shares worth $3.95M. The position accounts for 0.46% of the portfolio, ranked #24.

1st Global Advisors first reported a position in PFE in Q2 2013 and has held it in 17 quarters since. The position peaked at $4.07M in Q1 2017. 2,049 funds tracked by Wall St. Rank hold PFE as of Q2 2017.

  • 1st Global Advisors held 124,051 shares of Pfizer worth $3.95M as of Q2 2017.
  • 1st Global Advisors sold 1,269 Pfizer shares in Q2 2017, an estimated $40K.
  • Pfizer made up 0.46% of 1st Global Advisors's portfolio in Q2 2017, its #24 holding.
  • 1st Global Advisors first reported a position in Pfizer in Q2 2013 and has held it in 17 quarters since.
  • 1st Global Advisors's Pfizer position peaked at $4.07M in Q1 2017.
  • 2,049 funds tracked by Wall St. Rank held Pfizer as of Q2 2017.

Based on 1st Global Advisors's 13F filing for Q2 2017, filed 15 Aug 2017.